Changeflow GovPing Pharma & Drug Safety EPO Patent Publication: Enhancing Vaccine Immun...
Routine Rule Added Final

EPO Patent Publication: Enhancing Vaccine Immunogenicity

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Published March 18th, 2026
Detected March 25th, 2026
Email

Summary

The European Patent Office has published patent application EP4509185A2 concerning methods for enhancing the immunogenicity of vaccines using oral yeast beta-glucans. The patent application lists Memorial Sloan Kettering Cancer Center as the applicant.

What changed

European Patent Office publication EP4509185A2 details a method for improving the effectiveness of vaccines by administering oral yeast beta-glucans. The patent application, filed by Memorial Sloan Kettering Cancer Center, focuses on enhancing the immunogenicity of poorly immunogenic antigen-specific vaccines.

This publication represents a new patent application and does not impose immediate compliance obligations on regulated entities. However, it indicates potential advancements in vaccine technology and adjuvant development that may influence future pharmaceutical research and development strategies. Companies in the pharmaceutical and biotechnology sectors should monitor patent landscapes for emerging technologies.

Source document (simplified)

← EPO Patent Bulletin

METHODS OF ENHANCING IMMUNOGENICITY OF POORLY IMMUNOGENIC ANTIGEN-SPECIFIC VACCINES USING ORAL YEAST BETA-GLUCANS

Publication EP4509185A2 Kind: A2 Mar 18, 2026

Applicants

Memorial Sloan Kettering Cancer Center

Inventors

CHEUNG, Nai-Kong, MODAK, Shakeel, RAGUPATHI, Govind

IPC Classifications

A61K 31/716 20060101AFI20250317BHEP A61K 31/7016 20060101ALI20250317BHEP A61K 39/00 20060101ALI20250317BHEP A61K 39/12 20060101ALI20250317BHEP A61K 39/39 20060101ALI20250317BHEP C07K 16/28 20060101ALI20250317BHEP C07K 16/30 20060101ALI20250317BHEP A61P 31/00 20060101ALI20250317BHEP A61P 31/16 20060101ALI20250317BHEP A61P 35/00 20060101ALI20250317BHEP A61P 1/00 20060101ALI20250317BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

METHODS OF ENHANCING IMMUNOGENICITY OF POORLY IMMUNOGENIC ANTIGEN-SPECIFIC VACCINES USING ORAL YEAST BETA-GLUCANS

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Rule
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4509185A2

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Vaccine Development Adjuvant Research
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Vaccines Immunology Biotechnology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.